<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030235</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00053</org_study_id>
    <nct_id>NCT03030235</nct_id>
  </id_info>
  <brief_title>Dapagliflozin in PRESERVED Ejection Fraction Heart Failure</brief_title>
  <acronym>PRESERVED-HF</acronym>
  <official_title>Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Luke's Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Luke's Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared&#xD;
      with placebo, on heart failure, disease specific biomarkers, symptoms, health status and&#xD;
      quality of life in patients with chronic heart failure with preserved systolic function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of&#xD;
      once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (NTproBNP and&#xD;
      BNP), symptoms, health status, and quality of life in patients with chronic heart failure&#xD;
      with preserved systolic function. An imaging substudy will also be conducted to explore the&#xD;
      effects of dapagliflozin vs. placebo on various echocardiographic parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">August 13, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of dapagliflozin, as compared with placebo, on heart failure disease-specific health status (symptoms and physical limitations) in patients with chronic heart failure with preserved systolic function.</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in heart failure related health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart failure related health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score at 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in heart failure related health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NTproBNP at 6 and 12 weeks.</measure>
    <time_frame>Baseline to Week 6 and Week 12</time_frame>
    <description>Change from baseline in NTproBNP at 6 and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BNP at 6 and 12 weeks</measure>
    <time_frame>Baseline to Week 6 and Week 12</time_frame>
    <description>Change from baseline in BNP at 6 and 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6 minute walk test at 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in 6 minute walk test at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c over the treatment period (evaluated separately in patients with and without type 2 diabetes)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in HbA1c over the treatment period (evaluated separately in patients with and without type 2 diabetes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 5pts increase in KCCQ clinical summary score and KCCQ overall summary score at 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Proportion of patients with a ≥ 5pts increase in KCCQ clinical summary score and KCCQ overall summary score at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 20% decrease in NTproBNP at 6 and 12 weeks</measure>
    <time_frame>Baseline to Week 6 and Week 12</time_frame>
    <description>Proportion of patients with a ≥ 20% decrease in NTproBNP at 6 and 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP at 6 and 12 weeks</measure>
    <time_frame>Baseline to Week 6 and Week 12</time_frame>
    <description>Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP at 6 and 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight at 6 and 12 weeks</measure>
    <time_frame>Baseline to Week 6 and Week 12</time_frame>
    <description>Change in weight at 6 and 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure at 6 and 12 weeks</measure>
    <time_frame>Baseline to Week 6 and Week 12</time_frame>
    <description>Change in systolic blood pressure at 6 and 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Chronic Heart Failure With Preserved Systolic Function</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin 10 mg oral tablet, once daily, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dapagliflozin matching placebo oral tablet, once daily, for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Oral Tablet</intervention_name>
    <description>Dapagliflozin 10Mg Oral Tablet</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin matching placebo</intervention_name>
    <description>Dapagliflozin matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptoms of dyspnea (NYHA class II-IV) without evidence of a non-cardiac or ischemic&#xD;
             explanation for dyspnea&#xD;
&#xD;
          2. Ejection fraction (EF) ≥ 45% as determined on imaging study within 24 months of&#xD;
             enrolment with no change in clinical status suggesting potential for deterioration in&#xD;
             systolic function&#xD;
&#xD;
          3. Elevated NT-proBNP (≥ 225 pg/ml) or BNP (≥ 75 pg/ml). For patients with permanent&#xD;
             atrial fibrillation inclusion thresholds will be BNP ≥ 100 pg/mL or NTproBNP ≥ 375&#xD;
             pg/mL&#xD;
&#xD;
          4. Stable medical therapy for heart failure for 15 days as defined by: i. No addition or&#xD;
             removal of ACE, angiotensin receptor blockers (ARBs), valsartan/sacubitril,&#xD;
             beta-blockers, calcium channel blockers (CCBs) or aldosterone antagonists; ii.No&#xD;
             substantial change in dosage (100% or greater increase or decrease from baseline dose)&#xD;
             of ACE, ARBs, beta-blockers, CCBs or aldosterone antagonists&#xD;
&#xD;
          5. On a diuretic ≥15 days prior to screening visit and a stable diuretic therapy for 7&#xD;
             days&#xD;
&#xD;
          6. At least one of the following: i. Hospitalization for decompensated HF in the last 12&#xD;
             months; ii. Acute treatment for HF with intravenous loop diuretic or hemofiltration in&#xD;
             the last 12 months; iii. Mean pulmonary capillary wedge pressure ≥15 mmHg or LV end&#xD;
             diastolic pressure (LVEDP) ≥15 mmHg documented during catheterization at rest, or&#xD;
             pulmonary capillary wedge pressure or LVEDP ≥25 mmHg documented during catheterization&#xD;
             with exercise; iv. Structural heart disease evidenced by at least one of the following&#xD;
             echo findings (any local measurement made within the 24 months prior to screening&#xD;
             visit): a) left atrial (LA) enlargement defined by at least one of the following: LA&#xD;
             width ≥3.8cm or LA length ≥5.0 cm or LA area ≥20 cm2 or LA volume ≥55 mL or LA volume&#xD;
             index ≥29 mL/m2 b) or left ventricular hypertrophy (LVH) defined by septal thickness&#xD;
             or posterior wall thickness ≥1.1 cm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated heart failure (hospitalization for heart failure within 7 days prior to&#xD;
             screening)&#xD;
&#xD;
          2. History of type 1 diabetes&#xD;
&#xD;
          3. History of diabetic ketoacidosis&#xD;
&#xD;
          4. Estimated glomerular filtration rate (eGFR) &lt; 20 at the screening visit by modified&#xD;
             MDRD equation GFR (mL/min/1.73 m2 ) = 175 x (Scr) -1.154 x (Age)-0.203 x (0.742 if&#xD;
             female) x (1.210 if African American)&#xD;
&#xD;
          5. Admission for an acute coronary syndrome (ST-elevation MI, non-ST-elevation MI, or&#xD;
             unstable angina), percutaneous coronary intervention, or cardiac surgery within 30&#xD;
             days prior to the screening visit.&#xD;
&#xD;
          6. Admission for cardiac resynchronization therapy (CRT) within 90 days prior to the&#xD;
             screening visit.&#xD;
&#xD;
          7. Planned cardiovascular revascularization (percutaneous intervention or surgical) or&#xD;
             major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular&#xD;
             assist device, cardiac transplantation, or any other surgery requiring thoracotomy, or&#xD;
             transcatheter aortic valve replacement) or CRT within the 90 days after the screening&#xD;
             visit.&#xD;
&#xD;
          8. Participation in any interventional clinical trial (with an investigational drug or&#xD;
             device) that is not an observational registry within 15 days of the screening visit.&#xD;
&#xD;
          9. History of hypersensitivity to dapagliflozin&#xD;
&#xD;
         10. For women of child-bearing potential: Current or planned pregnancy or currently&#xD;
             lactating.&#xD;
&#xD;
         11. Life expectancy &lt;1 year at the screening visit&#xD;
&#xD;
         12. Patients who are volume depleted based upon physical examination at the time of the&#xD;
             screening or randomization visit&#xD;
&#xD;
         13. BNP &lt;75 pg/mL and NTproBNP&lt;225 pg/mL at the screening visit. For patients with&#xD;
             permanent atrial fibrillation exclusion thresholds will be BNP&lt;100 pg/mL and&#xD;
             NTproBNP&lt;375pg/mL.&#xD;
&#xD;
         14. Patients currently being treated with any SGLT-2 inhibitor (dapagliflozin,&#xD;
             canagliflozin, empagliflozin, ertugliflozin) or having received treatment with any&#xD;
             SGLT-2 inhibitor within the 12 weeks prior to the screening visit.&#xD;
&#xD;
         15. Average supine systolic BP &lt;100 mmHg at the screening or randomization visit&#xD;
&#xD;
         16. Current history of bladder cancer&#xD;
&#xD;
         17. Donation of blood or bone marrow 12 weeks prior to the screening visit and no planned&#xD;
             donations during the study period&#xD;
&#xD;
         18. Heart failure due to restrictive/infiltrative cardiomyopathy, active myocarditis,&#xD;
             constrictive pericarditis, severe stenotic valve disease, and HOCM (hypertrophic&#xD;
             obstructive cardiomyopathy).&#xD;
&#xD;
         19. Heart failure due to severe aortic or mitral regurgitation&#xD;
&#xD;
         20. Severe COPD thought to be a primary contributor to dyspnea&#xD;
&#xD;
         21. Isolated right heart failure due to pulmonary disease&#xD;
&#xD;
         22. Active and significant ischemia thought to be a primary contributor to dyspnea&#xD;
&#xD;
         23. Documentation of previous EF &lt; 45%, under stable conditions, within the past 36 months&#xD;
&#xD;
         24. Complex congenital heart disease&#xD;
&#xD;
         25. Uncontrolled hypertension, defined as systolic blood pressure ≥200 mmHg during the&#xD;
             screening visit (average value of three blood pressure measurements obtained in supine&#xD;
             position)&#xD;
&#xD;
         26. Any other condition that in the judgment of the investigator would jeopardize the&#xD;
             patient's participation in the study or that may interfere with the interpretation of&#xD;
             study data or if the patient is considered unlikely to comply with study procedures,&#xD;
             restrictions and requirements&#xD;
&#xD;
         27. Bariatric surgery within the past 6 months or planned bariatric surgery within the&#xD;
             study time course.&#xD;
&#xD;
         28. CardioMems device implantation within previous 4 weeks or planned CardioMems&#xD;
             implantation during study period&#xD;
&#xD;
         29. For echo substudy only: patients with ventricular paced rhythm or left bundle branch&#xD;
             block on the most recent clinically available 12-lead electrocardiogram.&#xD;
&#xD;
         30. For echo substudy only: permanent atrial fibrillation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>119 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Kosiborod, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saint Luke's Mid America Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Group of the Eastern Shore</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Heart Group Research Center</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem Research Insititute</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Medical Research</name>
      <address>
        <city>Hazel Crest</city>
        <state>Illinois</state>
        <zip>60429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF HealthCare Cardiovascular Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Cardiovascular Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Nephrology Associates</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://druginfo.nlm.nih.gov/drugportal/name/dapagliflozin</url>
    <description>Dapagliflozin information</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>dapagliflozin</keyword>
  <keyword>SGLT-2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

